Prenatal Intravenous Magnesium and Neurodevelopmental Outcomes in Offspring

To the Editor The MAGENTA trial showed that administration of intravenous magnesium sulfate prior to preterm birth at 30 to 34 weeks’ gestation did not improve offspring survival free of cerebral palsy at 2 years. No serious cardiovascular or respiratory adverse events were reported among the participants who received magnesium. This trial is important because births between 30 and 34 weeks’ gestation occur more commonly than those before 30 weeks’ gestation, and the use of prenatal magnesium may have varying benefits and risks depending on gestational age.